Tenelia Triple Combination Study

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

After a screening, a 2-week, single-blind placebo run-in, 200 patients will be randomized in a 1 : 1 ratio to the addition of either once-daily Teneligliptin 20mg or sitagliptin 100mg to ongoing stable doses of glimepiride in combination with metformin for 24 weeks.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Handok Inc.; Handok Pharmaceuticals Co., Ltd.
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

1. Patients with Type 2 Diabetes Mellitus

2. Adults aged ≥ 19 years old

3. Patients with HbA1c 7%~11% at Screening and Run-in visit

Exclusion Criteria:

-